A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Inclusion criteria:

• Be otherwise healthy on the basis of physical examination, medical history, vitalsigns, and 12-lead electrocardiogram (ECG) performed at screening

• Meets all the following disease activity criteria: a. Chronic atopic dermatitis (AD), according to American Academy of Dermatology Consensus Criteria with onset ofsymptoms at least 1 year prior to screening visit; b. Eczema area and severity index (EASI) score greater than or equal to (>=) 16 at the screening and Week 0; c.validated investigator global assessment for atopic dermatitis (vIGA-AD) score >= 3at screening and Week 0; d. >= 10% body surface area (BSA) of AD involvement atscreening and Week 0; e. Documented history (within 6 months before screening) ofeither inadequate response or inadvisability to medicated topical treatments for ADor inadequate response to systemic therapies (within 12 months before screening)

• Must sign an informed consent form (ICF) indicating that the participant understandsthe purpose of, and procedures required for, the study and is willing to participatein the study

• If willing to participate in the substudy, must sign a separate ICF for thecorresponding substudy (or substudies)

• Willing and able to comply with scheduled visits, treatment plan, laboratory tests,lifestyle restrictions, and other study procedures

Exclusion criteria:

• History of substance abuse or alcohol abuse within 1 year before screening

• In the investigator's opinion, any clinically significant results from the 12-leadECG, chemistry, hematology, or urinalysis laboratory tests obtained at the screeningvisit that would affect interpretation of study data or the participant's safety inthe study

• Known or suspected immunodeficiency, including history of invasive opportunisticinfections

• Previously received JNJ-95597528

• Has known hypersensitivity or intolerance to JNJ-95597528 or its excipients or toany biologic medication or known allergies, or clinically significant reactions tomurine, chimeric, monoclonal antibodies (mAbs), or antibody fragments